BCRX Biocryst Pharmaceuticals Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 0 P/E
- 43.10 P/S
- 7.72 P/B
- -0.68 EPS
- -229.93% Cash ROIC
- 1.26 Cash Ratio
- 0 / N/A % Dividend
- 861,045.00 Avg. Vol.
- 72.32M Shares
- 600.26M Market Cap.
BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
wsnewspublishers - Mar 24, 2015
Yarlagadda S. Babu Sells 12105 Shares of BioCryst Pharmaceuticals Stock ... - WKRB News
Seeking Alpha (registration) - Jan 27, 2015
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary ... - MarketWatch
Stafford Daily - Mar 9, 2015
Company Shares of BioCryst Pharmaceuticals, Inc. Drops by -1.52% - Winston View
Markets Wired - Mar 5, 2015
Insider Selling: BioCryst Pharmaceuticals VP Yarlagadda S. Babu Sells 10495 ... - Mideast Time
wsnewspublishers - Mar 25, 2015
Motley Fool - May 27, 2014
BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 ... - MarketWatch
Markets Wired - Feb 25, 2015
Insider Buying: Nancy J. Hutson Buys 10000 Shares of BioCryst ... - Dakota Financial News
Markets Wired - Jan 12, 2015
Bar and Graph Report - Mar 13, 2015
ETF Daily News - Aug 5, 2014
BioCryst Pharmaceuticals (BCRX) Continues to Rise on Potential Ebola Treatment - Equities.com